Oxford Genetics and University of Oxford Form Virus Production Pact

Biotechnology company, Oxford Genetics, has received a grant to develop packaging cell lines for virus bioproduction. Oxford Genetics will be working in collaboration with the University of Oxford in this $1 million project, to generate cell lines for the scalable manufacture of retrovirus and lentivirus vectors.

Oxford Genetics, who recently acquired facilities at the Oxford Science Park, is now looking to extend its product and service offering into the virus manufacturing space.

The program will span 12 months and follows the recent announcements from Oxford Genetics that is has expanded its board to include several industry experts, acquired new state-of-the-art cell-line development facilities, and received £2 million investment from Mercia Technologies. The business is now seeking early access partners working with therapeutic virus systems to allow scale-up validation of the systems it is developing.